Search Results
Showing 18 of 18 results
Meet Our People Beryl Ojwang
Beryl Ojwang MD MBA MPH Associate Medical Director Oncology Biosimilars North America Medical Affairs shares how artificial intelligence is bringing patient insights to Teva scientists
New R D Facility in Hungary will Double Annual Testing Capability
Go behind the scenes at Teva to Debrecen in Hungary where a new 2 4 million R D facility is helping to speed up production and get medicines to patients faster
Democratizing Science Big Pharma Joins Forces with Academia
Building cross sector and multidisciplinary collaborations developing innovative technology and supporting the next generation of entrepreneurs will all play an important part in developing the medicines of the future An industry shift in attitudes and working patterns is needed to embrace this new age and find new ways of operating At Teva this shift has already started
Straight Out of High School How Teva Develops the Next Generation of Professionals
Meta description An educational program in our Opava Czech Republic site is bringing together Teva s professionals and high schoolers
Teva goes to University Collaborating with Academia to Improve the Lives of Patients
Ongoing academic partnerships are the driving forces behind some of Teva s dynamic Research Development
New Trends in Advanced Analytics and AI for Patient Care
Data scientist Michal Melamed discusses the innovations she s most excited about in healthcare technology
Meet the Expert Ivana Šoljić Jerbić
Ivana Šoljić Jerbić lead scientist in the development of complex sterile medicines at Teva Croatia talks about her work collaborating with people all over the world Read more
Meet Our People Gregg DeRosa
Gregg DeRosa who leads Teva s Global Clinical Operations talks with us about his leadership style and more
Generic Medicines and Regulation Producing the World s Biggest Medicine Cabinet Safely and Effectively
Generic medicines are created to be the same as branded drugs whose patents have expired using the same active ingredients and producing the same clinical effects We explain how these more affordable versions of branded drugs are regulated to ensure that they are safe and effective
Breaking Boundaries How Diversity Fuels Innovation in Teva s R D Management Team
Meet Heather De Luca Head of Global Program Leadership R D Eric Hughes Head of Global R D and Chief Medical Officer and Sophie Lamle SVP Head of Innovative Medicines R D Together they offer valuable insights into how diversity particularly gender influences the development of groundbreaking ideas and solutions
Generics R D
Teva s Global R D organization is devoted to the development of new medicines devices and combination products that provide meaningful therapeutic benefit
Revolutionary Innovations in Medicine Propelled by AI and Cross Industry Collaboration
Take a look inside Israel s AION Labs which is being supported by Teva to transform the way big pharma works with the aim of discovering new medicines faster cheaper and more precisely
What Took Us Years Could Now Take Half the Time Innovation Is Redefining Pharma
AI and other technologies have significantly shortened the R D process in the pharma industry Dr Eran Harary of Teva Pharmaceuticals sheds light on innovation
Where Big Pharma Meets Academia Key Trends I m Watching
Dana Bar On Head of Global Academic Collaborations at Teva Global R D showcases the innovative ways pharmaceutical companies and academic institutions are collaborating to define the future of drug development
Meet the Expert Boglárka Szabóné Szikszai
Boglárka Szabóné Szikszai and her team are responsible for developing new and existing Active Pharmaceutical Ingredients in Teva s site in Debrecen Hungary
Meet the Expert Barak Zohar
Barak talks about his work developing biosimilars at Teva and how his curiosity drives him every day
Can AI driven digital biomarkers redefine diagnostics and clinical trials
Artificial Intelligence and advanced analytics technologies have huge potential to improve the world of health We talk to Teva employees who are using the technologies
Our goal is to lead the field of biosimilars just like we lead in generic medicines
Dr Nir Shapir VP of Teva s global research and development team and CMC Biosimilars division discusses Teva s entry into the biosimilars market and the complexity of manufacturing biopharmaceuticals Read the interview with Haaretz reprinted with permission
